Isomorphic Labs, the drug discovery subsidiary of Alphabet headed by Demis Hassabis, has completed a $5bn Series C funding round. Greenoaks and Sequoia Capital co-led the investment, which the company announced on Tuesday. The funding arrives six months after the firm raised $2.1bn in May.
Andreessen Horowitz joined as a new backer alongside several other investors, while existing supporters—Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund—all participated again. Alphabet itself made what Isomorphic described as continued substantial investment. The company noted that investors oversubscribed the round, though it declined to reveal its valuation. Bloomberg had previously reported the funding would value Isomorphic at roughly $50bn.
Accelerating the path to human trials
According to Hassabis, the capital injection will help propel Isomorphic toward clinical trials. "What we're trying to build is a platform to do hundreds of drugs a year," he told Bloomberg.
The company's IsoDDE drug design engine is generating encouraging preclinical findings across its own oncology and immunology initiatives, as well as through collaborations with external partners. Hassabis disclosed that more than 20 programmes are currently in development. Major pharmaceutical companies including Eli Lilly, Novartis and Johnson & Johnson are among Isomorphic's collaborators.
In January, Hassabis indicated that Isomorphic anticipated launching its first clinical trials by the end of 2026, though he declined to provide Bloomberg with an updated timeline. He stated the firm remains on schedule with regulatory submissions and expects to share further announcements during 2027. To date, no regulatory authority has greenlit a drug designed entirely through AI.
Beyond small-molecule therapeutics, Isomorphic intends to deploy the fresh capital to expand into "pretty much all modalities," Hassabis explained, encompassing large-molecule biologics.
Why the backers are betting big
Sequoia Capital partner Konstantine Buhler highlighted the company's technical foundation: "Isomorphic Labs is building foundational technology for the future of medicine." He explained to Bloomberg that Sequoia's confidence stems from Isomorphic's discovery of scaling laws for its models—meaning that performance continues to advance as the company increases computational resources and training data.
The funding round marks Isomorphic's first major capital raise since Hassabis stepped down as chief executive of Google DeepMind in August during an Alphabet reorganisation. He now serves as DeepMind's chair and Alphabet's chief scientist while continuing to lead Isomorphic.
Regarding computational infrastructure, Hassabis addressed concerns that have rippled through the AI sector following Jensen Huang's recent departure from Nvidia. "We've got very secure compute pipelines," Hassabis told Bloomberg. Google's development of its own AI chips provides Isomorphic with independent access to the processing power essential for its operations.
Isomorphic was founded in 2021 to leverage breakthroughs from Google DeepMind's AlphaFold protein structure prediction model. The company maintains its primary base in London, with additional offices in Cambridge, Massachusetts, and Lausanne.
Source: The Next Web



